Earnings
AbCellera Prepares Longer-Lasting Hot-Flash Drug To Get Ahead Of Potential Competitors
The successor could mean fewer injections and lower production costs, while the lead treatment remains on track for late-stage testing.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
Earnings
The successor could mean fewer injections and lower production costs, while the lead treatment remains on track for late-stage testing.
Earnings
Management expects several hundred million dollars in additional rocket spending in 2027, while analysts question reliability and reuse.
SEC Filings
Timur R. Turlov and his private holding company would owe cash if the seller's stock sales fall short.
SEC Filings
The investment partnerships hold 14,694,910 shares in the cancer-drug developer, and Farallon reports shared voting power.
SEC Filings
A change in Fate's outstanding share count triggered the update; Redmile reports 14.99% beneficial ownership.
SEC Filings
The reporting group still holds more than 12 million shares in the cancer-drug company after October and November sales.
Earnings
Customers booked eight missions for roughly $515 million during the quarter, even with the rocket's first flight pushed to 2027.
Earnings
Management expects the Helios ramp to concentrate growth in the second half of fiscal 2027, with supply shortages complicating execution.
Earnings
The data-center operator raised its adjusted earnings outlook as contracted power exceeded capacity available to sell.
SEC Filings
Malone still reports approximately 4.8% ownership through trusts and an LLC, including more than 13 million shares in his revocable trust.
SEC Filings
Subscriptions keep growing, while a $17.5 million investment valuation gain accounts for much of quarterly profit.
Earnings
A Granite State landfill write-off hurt quarterly earnings, while higher fuel fees prompted a higher annual sales forecast.